Health and Healthcare
Biotech Monday (CRIS, CGRB, EXEL, MNKD, PDLI, SQNM, TCM)
Published:
Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is $0.86 to $2.35.
Cougar Biotechnology, Inc. (NASDAQ: CGRB) down 23% to $17.75.
Exelixis (NASDAQ: EXEL) hit a new 5 year low this morning. Its down 7% to $5.38 on a 52 week low of $5.67 to $12.77. No special reason for the downturn aside from a market wide lack of interest in developmental-stage drugs.
MannKind Corp. (NASDAQ: MNKD) downgrades and fears of ending inhaled insulin development lead to a new all-time low. Shares are down 18% at $4.52 in mid-day trading. The 52 week range is $5.25 to $15.99.
PDL BioPharma (NASDAQ: PDLI) fell another 8% after the recent drops after it canceled its sale last week. Its shares hit lows of $10.12, another 52-week low.
Sequenom Inc. (NASDAQ: SQNM) down 17% on no new news. Shares are trading at $5.47 with a 52 week range of $2.93 to $11.63.
Tongjitang Chinese Medicines Co. (NYSE: TCM) shares are up over 33% to $8.83 in mid-day trading on news that the CEO and another board director submitted a proposal to acquire all outstanding shares and take the company private. The 52 week range is $6.57 to $12.88.
Rachel Lopez
March 10, 2008
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.